Realtime | Geld | Brief | Zeit |
---|---|---|---|
31,150 | 31,250 | 10:38 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
30.06. | BASTIDE: Bastide Groupe Sells Baywater Healthcare To Sapio Group | 349 | Actusnews Wire | Crewe, United Kingdom & Monza, Italy - 30th June 2025
Bastide le Confort Medical SA (hereinafter "Groupe Bastide") today announced that it has agreed to the sale of its subsidiary Baywater Healthcare... ► Artikel lesen | |
09.06. | BASTIDE: Disposal of CICADUM and MEDSOFT | 372 | Actusnews Wire | Caissargues, June 9, 2025
Bastide Groupe announced today the disposal of its French subsidiaries, Cicadum, 51%-owned, (signing subject to financing condition precedent) and Medsoft, 100%-owned... ► Artikel lesen | |
05.06. | BASTIDE: Disposal of DORGE and DYNA MEDICAL in Belgium | 355 | Actusnews Wire | Caissargues, June 5, 2025
Bastide Groupe announced today the disposal of its Belgian subsidiaries, Dorge Medic, which specializes in the sale and rental of medical equipment and products for... ► Artikel lesen | |
04.06. | BASTIDE: Respiratory care therapy: Baywater wins London region tender and consolidates its leading position in the UK | 359 | Actusnews Wire | Caissargues, June 4, 2025
After being chosen one year ago by the National Health Service (NHS) to be the exclusive operator for respiratory care (oxygen therapy) in the East of England region... ► Artikel lesen | |
15.05. | BASTIDE: Continued strong organic growth in Q3 2024-2025 at +7.7%: Home healthcare services up 10.4% and recovery of Homecare activities confirmed / 2024-2025 targets confirmed | 393 | Actusnews Wire | Caissargues, May 15, 2025
In € millions
2023-2024
published
2023-2024*
Adjusted
2024-2025
published
Change
First-quarter revenue
127.9
122.7
133.8
+9.1%
Second-quarter... ► Artikel lesen | |
BASTIDE LE CONFORT MEDICAL Aktie jetzt für 0€ handeln | |||||
19.03. | BASTIDE: 2024-2025 half-year results / Recurring operating margin at 9.1%, up 80 bps / Operating FCF positive at EUR 9.4 million / Improvement in financial leverage / upward revision of recurring operating margin target to 9.1% | 501 | Actusnews Wire | Caissargues, March 19, 2025 - Groupe Bastide, a leading European provider of home healthcare services, published its 2024-2025 half-year results on December 31, 2024. Groupe Bastide's 2024-2025... ► Artikel lesen | |
13.02. | BASTIDE: Organic growth of 8.4% in first-half 2024 2025: Home healthcare services up 10.2% and Return to growth in the Homecare business / 2024-2025 targets confirmed | 386 | Actusnews Wire | Caissargues, February 13, 2025
In € millions
2023-2024
published
2023-2024*
Adjusted
2024-2025
published
Change
First-quarter revenue
127.9
122.7
133.8
+9.1%
Second-quarter... ► Artikel lesen | |
08.01. | BASTIDE obtains an extended license to operate in Canada in the Respiratory Care segment / Sale of French stomatherapy subsidiary CICA PLUS | 322 | Actusnews Wire | Caissargues, January 8, 2025 - Groupe Bastide, one of Europe's leading players in home healthcare services, announces its newly extended license to operate in the field of respiratory care in British... ► Artikel lesen | |
14.11.24 | BASTIDE: Highly dynamic organic growth in Q1 2024-25 at 9.0%: 10.9% growth in home healthcare services and rebound in the homecare business, up 6.0% / Disposal of Swiss commercial business finalized and 2024-2025 targets confirmed | 403 | Actusnews Wire | Caissargues, November 14, 2024 - Groupe Bastide, a leading European provider of home healthcare services, has published its revenue for first-quarter 2024-2025, ending September 30, 2024.
In... ► Artikel lesen | |
04.11.24 | BASTIDE: 2024-2025 financial calendar | 312 | Actusnews Wire | Caissargues, November 4, 2024
Events
Dates*
2024-2025 Q1 Revenue
Thursday November 14, 2024
2024-2025 H1 Revenue
Thursday February 13, 2025
2024-2025 H1 Results
Wednesday... ► Artikel lesen | |
23.10.24 | BASTIDE: 2023-2024 annual results: Solid growth in revenue and recurring operating margin of 8.5%, exceeding the target / improved profitability and a focus on reducing debt in 2024-25 | 325 | Actusnews Wire | Caissargues, October 23, 2024 - Groupe Bastide, leading European provider of home healthcare services, announces its earnings for the 2023-2024 financial year ended 30 June 2024. The full-year... ► Artikel lesen | |
29.08.24 | BASTIDE: Annual revenue: EUR 530 million (up 8.2%) exceeding the target of EUR 520 million / Organic growth accelerated in fourth quarter 2023-2024: up 9.5% / Profitability target of 8.4% confirmed for 2023-2024 | 331 | Actusnews Wire | Caissargues, August 29, 2024
In € millions
2022-2023 published
2022-2023* restated
2023-2024 published
Change
Fourth-quarter revenue
127.9
122.2
134.5
+10.1%
Annual... ► Artikel lesen | |
25.07.24 | BASTIDE: Financing resources reinforced through a new syndicated loan - Medium-term financing secured and debt maturity extended | 572 | Actusnews Wire | Caissargues, July 25, 2024
Groupe Bastide announced today that it has set up a new financing contract for €375 million, including a syndicated loan and a revolving credit facility, as part of its... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ANSELL | 17,000 | -1,16 % | ANSELL LIMITED: Notice of Ansell FY25 Full Year Results Announcement | ||
AMBEA | 10,370 | -1,14 % | Ambea AB: Ambea's interim report January - March 2025 | Entry into Finnish market enables increased Nordic growth
CEO comments:
After the end of the quarter, we completed the acquisition of Validia in Finland, making us the only care provider with a strong... ► Artikel lesen | |
PROCEPT BIOROBOTICS | 58,34 | 0,00 % | Procept BioRobotics: BofA bestätigt Kaufempfehlung trotz geplanter Medicare-Kürzungen | ||
RXSIGHT | 7,350 | 0,00 % | Steris, Solventum upgraded, RxSight downgraded in Morgan Stanley's MedTech review | ||
ATRICURE | 29,260 | 0,00 % | AtriCure completes enrollment in stroke prevention trial | ||
FRESENIUS MEDICAL CARE | 45,260 | -1,48 % | DAX tiefer, Bitcoin, Silber stark: BASF, Lufthansa, BMW, Rheinmetall, FMC, Siemens Energy ... | Die Ankündigung von Donald Trump, Importe aus der EU ab 1. August mit einem Zoll in Höhe von 30 Prozent belegen zu wollen, hat beim DAX am Freitag Bremsspuren hinterlassen. Der deutsche Leitindex verabschiedete... ► Artikel lesen | |
GENEDX | 78,00 | 0,00 % | Rackspace US, Inc.: Rackspace Technology und Sema4.ai stellen die erste skalierbare KI-Agent-Lösung für Unternehmen vor | Die unternehmensgerechte Lösung schließt die Lücke zwischen KI-Experimenten und umfassender TransformationSAN ANTONIO, June 18, 2025®) und die Anwendungsmanagement-Expertise von Rackspace mit der fortschrittlichen... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 46,140 | +0,07 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
NUTEX HEALTH | 113,81 | 0,00 % | Nutex Health: Aktionäre wählen Vorstand und genehmigen Planänderungen auf Hauptversammlung | ||
FRESENIUS | 40,890 | 0,00 % | Aktie von Fresenius SE & Co. KGaA heute am Aktienmarkt kaum gefragt: Kurs fällt (41,21 €) | An der deutschen Börse notiert die Fresenius SE & Co. KGaA-Aktie derzeit ein wenig leichter. Die Aktie notiert zur Stunde bei 41,21 Euro. Der Anteilsschein von Fresenius+Co KgaA verzeichnet aktuell... ► Artikel lesen | |
MIMEDX | 6,420 | 0,00 % | MiMedx Group, Inc: MIMEDX Comments on Proposed Medicare Reimbursement Rule Changes for CY 2026 | MARIETTA, Ga., July 15, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today commented on the Centers for Medicare and Medicaid Services ("CMS") release of... ► Artikel lesen | |
GERRESHEIMER | 47,720 | +1,23 % | UBS stuft GERRESHEIMER AG auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat das Kursziel für Gerresheimer von 97 auf 75 Euro gesenkt, aber die Einstufung auf "Buy" belassen. Analyst Olivier Calvet arbeitete am Montag... ► Artikel lesen | |
INCANNEX HEALTHCARE | 0,598 | 0,00 % | Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA) | NEW YORK and MELBOURNE, Australia, April 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing... ► Artikel lesen | |
PHETON | 22,230 | 0,00 % | Pheton Holdings Ltd - S-8, Securities to be offered to employees in employee benefit plans | ||
PROGYNY | 22,000 | 0,00 % | Progyny, Inc. Provides Business Update and Announces Details for Its Second Quarter 2025 Results Report | Operational and Financial Flexibility Enhanced Through New Credit FacilitySecond Quarter Results Anticipated to be Slightly Above Previously Provided Financial Guidance NEW YORK, July 08, 2025 (GLOBE... ► Artikel lesen |